Financial Performance - Citius Oncology reported $3.9 million in revenue for the fiscal first quarter 2026, marking its first reported revenue following the launch of LYMPHIR in December 2025[1][7]. - The net loss for the quarter was $5.5 million, or $(0.06) per share, compared to a net loss of $6.7 million, or $(0.09) per share, for the prior-year period[7][14]. - The net loss for 2025 was $5,534,069, an improvement from a net loss of $6,659,205 in 2024[16]. - Stock-based compensation expense increased to $3,956,050 in 2025 from $1,808,478 in 2024[16]. - Net cash used in operating activities was $(7,354,946) for 2025, with significant changes in accounts receivable and inventory[16]. - License payments for investing activities amounted to $(4,400,000) in 2025[16]. - Net proceeds from the issuance of common stock were $15,125,489, contributing positively to financing activities[16]. - The net change in cash and cash equivalents for 2025 was an increase of $3,370,543[16]. - Cash and cash equivalents at the end of the period reached $7,295,451, up from $3,924,908 at the beginning[16]. - Interest paid during the period was $14,460[16]. Expenses - Research and development expenses decreased to $1.0 million from $1.3 million in the prior-year period, reflecting reduced clinical development activity[7][14]. - General and administrative expenses were $2.9 million, down from $3.3 million in the prior-year period[7][14]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is growing, indicating a significant opportunity in an underserved market[6][7]. - Citius Oncology is advancing an international access strategy through regional distribution partners and Named Patient Programs in key European and Middle Eastern markets[7][4]. - The company is focused on expanding its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform[2][7]. Strategic Focus - Citius Oncology is evaluating strategic opportunities to enhance long-term shareholder value while maintaining capital management[3][7]. - The company established a nationwide specialty distribution infrastructure to ensure immediate product availability and support rapid physician adoption of LYMPHIR[4][7].
Citius Oncology, Inc.(CTOR) - 2025 Q4 - Annual Results